CG
FULC icon

Cutler Group’s Fulcrum Therapeutics FULC Stock Holding History

Cutler Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$1K – 5105
2022
Q2 		$1K Buy
+1,000
New +$9.77K ﹤0.01% 4572
2021
Q4 		– Sell
-30,900
Closed -$14K – 5589
2021
Q3 		$14K Buy
+30,900
New +$585K ﹤0.01% 3648

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cutler Group's FULC Position: Q1 2023 in Review

Cutler Group sold out of Fulcrum Therapeutics (FULC) in Q1 2023, closing a stake of 500 shares — an estimated $3K sold.

Cutler Group first reported a position in FULC in Q3 2021 and held it in 6 quarters. The position peaked at $25K in Q3 2021. 116 funds tracked by Wall St. Rank hold FULC as of Q1 2023.

  • Cutler Group reported no remaining Fulcrum Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 500 Fulcrum Therapeutics shares in Q1 2023, an estimated $3K.
  • Cutler Group first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 6 quarters.
  • Cutler Group's Fulcrum Therapeutics position peaked at $25K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.